News

Public · Published

Immuneering to Highlight Atebimetinib's Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium

Immuneering announced that two abstracts on atebimetinib, its investigational cancer drug, were accepted for presentation at the November 17–19, 2026 EORTC-NCI-AACR symposium. They will present preclinical findings on combinations in pancreatic and anaplastic thyroid cancers; atebimetinib is also being evaluated in a Phase 3 pancreatic cancer trial.

Published:

Updated:

What happened

Immuneering announced that two abstracts on atebimetinib, its investigational cancer drug, were accepted for presentation at the November 17–19, 2026 EORTC-NCI-AACR symposium. They will present preclinical findings on combinations in pancreatic and anaplastic thyroid cancers; atebimetinib is also being evaluated in a Phase 3 pancreatic cancer trial.

Confirmed

Global impact / market context

The findings may guide which drug combinations researchers test next, potentially shaping atebimetinib’s development costs and future sales opportunity if benefits are later shown in patients. For now, preclinical evidence does not establish treatment benefit, and the Phase 3 trial remains a key test in pancreatic cancer.

Analyst inference

The article cites earlier Phase 2 results of 17.3 months median overall survival for first-line pancreatic cancer patients receiving atebimetinib with chemotherapy. Those results are distinct from the new preclinical findings; the Phase 3 trial could determine whether the combination supports broader clinical use and investment expectations.

Analyst inference

What to watch

  1. At the November 17–19 symposium, look for details on which targeted therapies were combined with atebimetinib and whether the preclinical results identify combinations for further testing. Analyst inference
  2. Watch for updates from Phase 3 MAPKeeper 301 in first-line pancreatic cancer; patient results could influence whether Immuneering advances atebimetinib toward wider testing or use. Analyst inference
  3. Further studies would need to test these preclinical combinations in people; without patient evidence, they cannot establish treatment benefit or show that combination development can generate sales. Analyst inference

Evidence